Norfolk families affected by cystic fibrosis push for life-changing treatment to be made available amid price row

PUBLISHED: 10:27 24 April 2018 | UPDATED: 10:27 24 April 2018

Ellie Loades. Photo: Loades family

Ellie Loades. Photo: Loades family


A drug manufacturer has been urged to lower the price of a life-changing treatment for cystic fibrosis (CF) sufferers so it can be made available on the NHS.

Ellie Loades' parents Nick and Elaine. Picture: Ian BurtEllie Loades' parents Nick and Elaine. Picture: Ian Burt

Health ministers Steve Brine and Lord O’Shaughnessy called on Vertex Pharmaceuticals, which makes the drug Orkambi, to bring negotiations over cost to “an urgent resolution”.

The drug is not currently available on the NHS because it is not considered cost-effective, but has been shown in clinical trials to improve lung function and respiratory symptoms.

And families in Norfolk affected by the condition have thrown their support behind the medication being made available.

Nick Loades’ daughter Ellie, from Colkirk, died aged 16 in November 2013 - she was diagnosed with CF at birth.

CF sufferer Ryan Hughes. Photo: Liz CoatesCF sufferer Ryan Hughes. Photo: Liz Coates

Since, he and wife Elaine started the charity, Ellie’s Love, and have campaigned for improved treatment.

He said: “I think it’s a brilliant idea that the drug is here but it’s ridiculous we are having to battle with the pricing.”

Mr Loades said while Ellie was alive, they had a similar battle over medication which could be given at home instead of at hospital.

As Mrs Loades suffers with multiple sclerosis (MS) when Ellie went into hospital she would have to go to respite care.

But potential treatment for Ellie at home was denied because of the cost.

“It has a horrendous impact,” Mr Loades said.

And the drug’s effect of improving lung function would be beneficial, he added.

“I can just imagine it because when you go into hospital it’s the first thing they measure, it’s so disheartening when it’s bad.

“I just think they’re playing with children’s lives. If Ellie was still here we’d be fighting for it, [the drug company] is holding the NHS to ransom.”

Gina Hughes from Ormesby St Michael, whose 23-year-old son Ryan has CF, hoped the introduction could mean a wider range of drugs being made available.

She said: “Although this drug wouldn’t help Ryan because of his genetics, it could open doors to other drugs being used.”

The family were told an equivalent drug for Ryan’s form of CF was still five years away - Orkambi is for people with the F508del mutation, which causes the production of an abnormal protein that disrupts how water and chloride are transported in the body.

But Mrs Hughes said any improvements would save hospital admissions - and therefore money - in the long run.

“It does make me angry when they say it costs this, it costs that,” she said. “I know it does seem a lot of money but when Ryan was last in hospital that admission cost £55,000. It’s not a cure but it will alleviate symptoms.”

NHS England has submitted a counter-offer to a deal proposed by the manufacturer but is awaiting a response.

Cystic fibrosis is a life-shortening genetic condition that causes fatal lung damage and affects around 10,400 people in the UK.

Only around half of those with cystic fibrosis live to celebrate their 40th birthday.

A Vertex spokesperson said: “We are pleased that the government is in agreement that we urgently need to find a solution to get our medicines to cystic fibrosis patients as soon as possible and are encouraged that we already have a date in the diary in the coming days to start a meaningful dialogue.

“As we previously said, negotiations over email are rarely productive so we are surprised to be asked to respond to a letter via the media that we have not yet received.

“The current counter offer amounts to a refusal to make any additional funding available for ORKAMBI® (lumacaftor/ivacaftor) or future medicines.

“We have responded to all requests for further information and look forward to discussing them with NHS England this week. We hope the NHS truly values the transformative nature of our medicines in a manner consistent with the value applied to KALYDECO® (ivacafator), which is available through the NHS and was last positively reviewed just over a year ago.

“We hope we can agree an approach with NHS England that benefits all eligible patients equally, as soon as possible. We call on the NHS to bring a positive and flexible approach in the best interest of CF patients.”

Other news

Yesterday, 16:58

Swaffham town councillors have agreed to apply for a £6 million government loan to fund the development of 51 new homes.

Yesterday, 18:30

A Swaffham grain trader has bought a Yorkshire competitor in an undisclosed-value deal.

Yesterday, 15:36

A First World War memorial campaign led by former head of the army Lord Dannatt will see 6ft tall Tommy silhouette statues erected around the county.

Yesterday, 13:17

A Swaffham based charity which aims to provide entertainment and activities for older people is hosting a Big Weekend event in September.

Most Read

Yesterday, 16:58

Swaffham town councillors have agreed to apply for a £6 million government loan to fund the development of 51 new homes.

Read more
Yesterday, 08:49

The Heritage at Risk Programme (HAR) was launched by Historic England and is used to help assess the overall state of the country’s heritage sites.

Read more
Yesterday, 06:26

Farmer’s land which is due to be dug up for offshore windfarm cables has previously carried a “radioactive risk” following a plane crash 22 years ago, secret documents reveal today.

Read more
Environment Agency
Wednesday, June 13, 2018

A landmark environmental centre, which helped to educate school children across the Norfolk about food, energy and transport, has suddenly announce it will close after nearly 20 years.

Read more
Breckland Council
Tuesday, February 27, 2018

An animal charity volunteer is hoping to have her most successful rehoming event.

Read more

Local Weather



max temp: 17°C

min temp: 16°C

Digital Edition

Read the Watton and Swaffham Times e-edition today

Show Job Lists

Newsletter Sign Up

Watton and Swaffham Times weekly newsletter
Sign up to receive our regular email newsletter

Our Privacy Policy